ReviewSN comprehensive clinical medicine2020
Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review.
Review in SN comprehensive clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
169 citing papers in PubMed, 2 syntheses or guidelines pooled it, 296 citations in OpenAlex.
- Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.Annals of hematology · 2023Pooled it
- Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review.European journal of haematology · 2023Pooled it
- Mechanisms and impact of long COVID: pathophysiology, neuropsychiatric effects and vaccination.Frontiers in immunology · 2026Review
- Paediatric Hospitalised Immune Thrombocytopenia in Real-Life Recent Viral Infection Outbreaks: A Retrospective Study.Life (Basel, Switzerland) · 2025Article
- Thrombocytopenia in murine schistosomiasis is associated with platelet uptake by liver macrophages that have a distinct activation phenotype.PLoS pathogens · 2025Article
- Evans Syndrome and COVID-19 Infection or Vaccination: A Systematic Review of Case Reports.Journal of hematology · 2025Review
- Pediatric autoimmune diseases in the light of COVID-19 pandemic, A retrospective observational big data study.Journal of translational autoimmunity · 2025Article
- New-onset hematologic disorders following COVID-19 vaccination: a systematic review.Clinical and experimental vaccine research · 2025Article
- Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.PloS one · 2025Article
- Post-COVID-19: Hematological Factors Changes in Patients at Three-time Intervals.Current medicinal chemistry · 2025Article
- Inflammatory, Hematological, and Biochemical Biomarkers in COVID-19 Patients.Immunity, inflammation and disease · 2024Article
- Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy.Hematology reports · 2024Article
- Assessing the impact of COVID-19 on acute leukemia patients: a comparative analysis of hematological and biochemical parameters.BMC infectious diseases · 2024Article
- Characterization of Unique Pathological Features of COVID-Associated Coagulopathy: Studies with AC70 hACE2 Transgenic Mice Highly Permissive to SARS-CoV-2 Infection.PLoS pathogens · 2024Article
- Antibodies against Platelet Glycoproteins in Clinically Suspected VITT Patients.Antibodies (Basel, Switzerland) · 2024Article
- The Aftermath of COVID-19: Exploring the Long-Term Effects on Organ Systems.Biomedicines · 2024Review
- Immune thrombocytopaenic purpura following COVID-19 infection masquerading as senile purpura.BMJ case reports · 2024Article
- Egyptian Pediatric Guidelines for the Management of Children with Isolated Thrombocytopenia Using the Adapted ADAPTE Methodology-A Limited-Resource Country Perspective.Children (Basel, Switzerland) · 2024Article
- Can iron chelators ameliorate viral infections?Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Review
- Complex changes in serum protein levels in COVID-19 convalescents.Scientific reports · 2024Article
109 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia, often known as immune thrombocytopenic purpura (ITP), has emerged as an important complication of COVID-19. A systematic review was done to analyze the clinical profile and outcomes in a total of 45 cases of new-onset ITP in COVID-19 patients described in literature until date. A comprehensive approach is essential for diagnosing COVID-19-associated ITP after excluding several concomitant factors that can cause thrombocytopenia in COVID-19. Majority of ITP cases (71%) were found to be elderly (> 50 years) and 75% cases had moderate-to-severe COVID-19. Three patients (7%) were in the pediatric age group. Reports of ITP in asymptomatic COVID-19 patients (7%) underscore the need for COVID-19 testing in newly diagnosed patients with ITP irrespective of COVID-19 symptoms amid this pandemic. ITP onset occurred in 20% cases 3 weeks after onset of COVID-19 symptoms, with many reports after clinical recovery. SARS-CoV-2-mediated immune thrombocytopenia can be attributed to the underlying immune dysregulation, susceptibility mutations in SOCS 1, and other mechanisms, including molecular mimicry, cryptic antigen expression, and epitope spreading. No bleeding manifestations were reported in 31% cases at diagnosis. Severe life-threatening bleeding was uncommon. One case of mortality was attributed to intracranial hemorrhage. Secondary Evans syndrome was diagnosed in one case. Good initial response to short course of glucocorticoids and intravenous immunoglobulin has been found with the exception of delayed lag response in one case. Thrombopoietin receptor agonist usage as a second-line agent has been noted in few cases for short duration with no adverse events. In the relatively short follow-up period, four relapses of ITP were found.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.